These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 23714473

  • 21. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG, Jiang H, Lim-Fat MJ, Sahebjam S, Kiehl TR, Karamchandani J, Coire C, Chung C, Millar BA, Laperriere N, Mason WP.
    Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
    [Abstract] [Full Text] [Related]

  • 22. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
    Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski CM, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Chen W, Iafrate AJ, Chi AS, Zagzag D, Golfinos JG, Placantonakis DG, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M.
    Neuro Oncol; 2019 Sep 06; 21(9):1164-1174. PubMed ID: 31140557
    [Abstract] [Full Text] [Related]

  • 23. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P, Kucukodaci Z, Gundogdu G, Bilgic B.
    Turk Neurosurg; 2017 Sep 06; 27(5):682-689. PubMed ID: 27651340
    [Abstract] [Full Text] [Related]

  • 24. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 25. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
    Sathornsumetee S, Cheunsuchon P, Sangruchi T.
    World Neurosurg; 2016 Jul 01; 91():518-523.e1. PubMed ID: 26960282
    [Abstract] [Full Text] [Related]

  • 26. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
    Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K.
    Brain Pathol; 2008 Jul 01; 18(3):360-9. PubMed ID: 18371182
    [Abstract] [Full Text] [Related]

  • 27. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.
    Iwadate Y, Matsutani T, Shinozaki N, Saeki N.
    Anticancer Res; 2011 Dec 01; 31(12):4475-9. PubMed ID: 22199318
    [Abstract] [Full Text] [Related]

  • 28. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
    Khan KA, Abbasi AN, Ali N.
    J Coll Physicians Surg Pak; 2014 Dec 01; 24(12):935-9. PubMed ID: 25523732
    [Abstract] [Full Text] [Related]

  • 29. Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted).
    Anderson MD, Gilbert MR.
    J Natl Compr Canc Netw; 2014 May 01; 12(5):665-72. PubMed ID: 24812135
    [Abstract] [Full Text] [Related]

  • 30. New treatment paradigm for patients with anaplastic oligodendroglial tumors.
    Polivka J, Polivka J, Rohan V, Topolcan O.
    Anticancer Res; 2014 Apr 01; 34(4):1587-94. PubMed ID: 24692686
    [Abstract] [Full Text] [Related]

  • 31. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y, Matsutani T, Hara A, Hirono S, Ikegami S, Kobayashi M, Ito D, Kawauchi D, Horiguchi K, Tamiya A, Higuchi Y.
    J Neurooncol; 2019 Jan 01; 141(1):205-211. PubMed ID: 30565028
    [Abstract] [Full Text] [Related]

  • 32. Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy.
    Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S, Hayashi K, Iwaki T, Sasaki T.
    Neurol Res; 2007 Oct 01; 29(7):723-6. PubMed ID: 17553214
    [Abstract] [Full Text] [Related]

  • 33. Advances in the biology and treatment of oligodendrogliomas.
    van den Bent MJ.
    Curr Opin Neurol; 2004 Dec 01; 17(6):675-80. PubMed ID: 15542975
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
    Cairncross G, Jenkins R.
    Cancer J; 2008 Dec 01; 14(6):352-7. PubMed ID: 19060598
    [Abstract] [Full Text] [Related]

  • 36. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM, Lesniak MS.
    Expert Rev Neurother; 2005 Nov 01; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [Abstract] [Full Text] [Related]

  • 37. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
    Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.
    Neuro Oncol; 2012 Sep 01; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH.
    Neuropathology; 2007 Feb 01; 27(1):10-20. PubMed ID: 17319279
    [Abstract] [Full Text] [Related]

  • 40. Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri.
    Schiff D.
    Neurology; 2003 Aug 12; 61(3):425; author reply 425. PubMed ID: 12913224
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.